- ICH GCP
- USA klinikai vizsgálatok nyilvántartása
- Klinikai vizsgálat NCT07803887
Effect of Adding a Biceps Femoris Short Head Block to Adductor Canal Block for Analgesia After Total Knee Arthroplasty (BiFeS-TKA)
Analgesic Efficacy of Adding a Short Head of the Biceps Femoris Muscle Block to the Adductor Canal Block in Total Knee Arthroplasty: A Prospective, Randomized, Controlled Trial
A tanulmány áttekintése
Állapot
Körülmények
Részletes leírás
Background
Total knee arthroplasty (TKA) is the definitive surgical treatment for end-stage knee osteoarthritis and is one of the most frequently performed orthopedic procedures worldwide. Despite advances in multimodal analgesic strategies, postoperative pain following TKA remains a major clinical challenge. Inadequate pain control may delay early mobilization, impair functional recovery, prolong hospitalization, increase opioid consumption, and reduce patient satisfaction. Therefore, optimization of regional anesthesia techniques continues to be an important component of enhanced recovery protocols after TKA.
Ultrasound-guided adductor canal block (ACB) has become a widely accepted motor-sparing regional analgesic technique for TKA because it provides effective analgesia to the anteromedial aspect of the knee while largely preserving quadriceps muscle strength. Nevertheless, the posterior compartment of the knee receives sensory innervation from branches of the sciatic nerve that are not consistently anesthetized by ACB alone. Consequently, residual posterior knee pain remains a common limitation of this technique.
The ultrasound-guided biceps femoris short head (BiFeS) block is a recently described regional anesthesia technique that targets the posterolateral sensory innervation of the knee through deposition of local anesthetic within the fascial plane adjacent to the short head of the biceps femoris muscle. Anatomical and preliminary clinical investigations suggest that this technique may provide additional analgesic coverage of the posterior knee while preserving motor function. However, evidence regarding its clinical efficacy as an adjunct to ACB in patients undergoing primary TKA remains limited.
Study Objectives
The objective of this study is to determine whether the addition of an ultrasound-guided BiFeS block to a standard ultrasound-guided ACB provides superior postoperative analgesia compared with ultrasound-guided ACB alone in patients undergoing primary unilateral TKA under spinal anesthesia.
Study Design
This is a prospective, single-center, parallel-group, randomized controlled clinical trial. Eligible participants will be randomly assigned in a 1:1 ratio to receive either an ultrasound-guided adductor canal block or an ultrasound-guided adductor canal block combined with a biceps femoris short head block before surgery. All patients underwent total knee arthroplasty under single-shot spinal anesthesia with 15 mg of hyperbaric bupivacaine. No periarticular local infiltration analgesia was performed by the surgical team. Postoperatively, all patients received a standardized multimodal analgesic regimen consisting of intravenous paracetamol (1 g) administered every 8 hours. Rescue analgesia consisted of intravenous tramadol (100 mg), which was administered when the Numeric Rating Scale (NRS) pain score was ≥4.
Outcome Assessment
The primary endpoint is cumulative intravenous morphine consumption (mg) from arrival in the post-anesthesia care unit until 48 hours after surgery. Secondary endpoints include postoperative pain intensity assessed using the Numeric Rating Scale (NRS), time to first rescue analgesic administration, quadriceps muscle strength, functional recovery assessed by the Timed Up and Go test and knee range of motion, quality of postoperative recovery (QoR-15), postoperative nausea and vomiting, patient and surgeon satisfaction, length of hospital stay, and block-related adverse events.
Clinical Significance
This study is designed to provide high-quality evidence regarding the potential clinical benefit of incorporating the BiFeS block into contemporary multimodal analgesic protocols for total knee arthroplasty. If the combined regional analgesic approach demonstrates improved postoperative analgesia while preserving motor function, it may represent an effective strategy to facilitate enhanced recovery after surgery and reduce perioperative opioid requirements.
Tanulmány típusa
Beiratkozás (Becsült)
Fázis
- Nem alkalmazható
Kapcsolatok és helyek
Tanulmányi kapcsolat
- Név: Nilgun Kavrut Ozturk, MD,Professor
- Telefonszám: +905334196049
- E-mail: kavrut@yahoo.com
Tanulmányozza a kapcsolattartók biztonsági mentését
- Név: Serhat Gulersen, MD,
- Telefonszám: +905445336784
- E-mail: serhatgulersen@gmail.com
Tanulmányi helyek
-
-
Antalya
-
Antalya, Antalya, Törökország (Türkiye), 07100
- Antalya Training and Research Hospital
-
Kapcsolatba lépni:
- Nilgun Kavrut Ozturk, MD, Professor
- Telefonszám: +95334196049
- E-mail: kavrut@yahoo.com
-
Kapcsolatba lépni:
- Serhat Gulersen, MD
- Telefonszám: +905445336784
- E-mail: serhatgulersen@gmail.com
-
Kutatásvezető:
- Serhat Gulersen, MD,
-
-
Részvételi kritériumok
Jogosultsági kritériumok
Tanulmányozható életkorok
- Felnőtt
- Idősebb felnőtt
Egészséges önkénteseket fogad
Leírás
Inclusion Criteria:
- Scheduled for elective primary unilateral total knee arthroplasty under spinal -anesthesia.
- American Society of Anesthesiologists (ASA) physical status I-III.
- Body mass index (BMI) <40 kg/m².
- Ability to understand the study procedures and provide written informed consent.
Exclusion Criteria:
- Refusal to participate or inability to provide informed consent.
- Body mass index 40 kg/m2 or higher.
- ASA physical status IV or V.
- Known allergy or hypersensitivity to local anesthetics, opioids, or other study -medications.
- Pregnancy or breastfeeding.
- Uncontrolled psychiatric disease or severe anxiety interfering with study participation.
- Pre-existing neuromuscular disease or peripheral neuropathy involving the operative limb.
- Chronic opioid use or opioid dependence.
- Chronic pain syndrome requiring regular analgesic therapy.
- Severe hepatic or renal insufficiency.
- Contraindications to spinal anesthesia or peripheral nerve block, including -coagulopathy, thrombocytopenia, local infection at the injection site, or patient refusal.
- Planned bilateral or revision total knee arthroplasty.
Tanulási terv
Hogyan készül a tanulmány?
Tervezési részletek
- Elsődleges cél: Kezelés
- Kiosztás: Véletlenszerűsített
- Beavatkozó modell: Párhuzamos hozzárendelés
- Maszkolás: Kettős
Fegyverek és beavatkozások
Résztvevő csoport / kar |
Beavatkozás / kezelés |
|---|---|
|
Aktív összehasonlító: Ultrasound-Guided Adductor Canal Block
Participants assigned to this arm will receive an ultrasound-guided adductor canal block before the induction of spinal anesthesia for primary unilateral total knee arthroplasty.
All regional blocks will be performed according to a standardized study protocol.
Perioperative anesthetic management, surgical procedures, and postoperative multimodal analgesia will be standardized for all participants.
|
An ultrasound-guided adductor canal block will be performed before the induction of spinal anesthesia using a standardized technique.
Following ultrasound identification of the adductor canal, 30 mL of 0.25% bupivacaine will be injected into the adductor canal adjacent to the femoral artery to provide perioperative analgesia for primary unilateral total knee arthroplasty.
|
|
Kísérleti: Ultrasound-Guided Adductor Canal Block Combined With Biceps Femoris Short Head Block
Participants assigned to this arm will receive an ultrasound-guided adductor canal block combined with an ultrasound-guided biceps femoris short head block before spinal anesthesia for primary unilateral total knee arthroplasty.
Both regional blocks will be performed according to a standardized study protocol.
Perioperative anesthetic management, surgical procedures, and postoperative multimodal analgesic regimens will be standardized for all participants.
|
An ultrasound-guided adductor canal block will be performed before the induction of spinal anesthesia using a standardized technique.
Following ultrasound identification of the adductor canal, 30 mL of 0.25% bupivacaine will be injected into the adductor canal adjacent to the femoral artery to provide perioperative analgesia for primary unilateral total knee arthroplasty.
An ultrasound-guided biceps femoris short head block will be performed before the induction of spinal anesthesia using a standardized technique.
Following ultrasound identification of the fascial plane adjacent to the short head of the biceps femoris muscle, 20 mL of 0.25% bupivacaine will be administered to provide additional posterolateral knee analgesia as an adjunct to the adductor canal block.
|
Mit mér a tanulmány?
Elsődleges eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
|---|---|---|
|
Cumulative Opioid Consumption
Időkeret: From arrival in the post-anesthesia care unit until 48 hours after surgery
|
Cumulative opioid consumption during the first 48 postoperative hours, recorded as intravenous morphine equivalent dose (mg).
|
From arrival in the post-anesthesia care unit until 48 hours after surgery
|
Másodlagos eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
|---|---|---|
|
Postoperative Pain Intensity
Időkeret: 4, 8, 12, 24, and 48 hours after surgery
|
Postoperative pain intensity will be assessed using the 11-point Numeric Rating Scale (NRS).
Scores range from 0 to 10, where 0 indicates no pain and 10 indicates the worst imaginable pain.
Pain will be evaluated both at rest and during knee flexion.
Lower scores indicate better postoperative analgesia.
|
4, 8, 12, 24, and 48 hours after surgery
|
|
Time to First Rescue Analgesic Administration
Időkeret: During the first 48 postoperative hours
|
Time from completion of surgery to the first administration of rescue analgesic medication, recorded in hours.
Longer time intervals indicate prolonged postoperative analgesic effectiveness.
|
During the first 48 postoperative hours
|
|
Quadriceps Muscle Strength
Időkeret: Preoperatively and at 8, 24, and 48 hours after surgery
|
Quadriceps muscle strength will be assessed using the Manual Muscle Testing (MMT) Scale, ranging from 0 to 5, where 0 represents no visible muscle contraction and 5 represents normal muscle strength against full resistance.
Higher scores indicate greater quadriceps muscle strength.
|
Preoperatively and at 8, 24, and 48 hours after surgery
|
|
Functional Mobility
Időkeret: 24 and 48 hours after surgery
|
Functional mobility will be evaluated using the Timed Up and Go (TUG) Test.
The total time (seconds) required to stand from a seated position, walk 3 meters, turn, return, and sit down will be recorded.
Shorter completion times indicate better functional mobility.
Participants who were unable to perform the TUG test independently at 24 hours after surgery were withdrawn from the study according to the study protocol.
|
24 and 48 hours after surgery
|
|
Knee Range of Motion
Időkeret: Preoperatively and at 12 and 24 hours after surgery
|
Active knee flexion range of motion will be measured in the supine position using a standard goniometer.
The maximum active knee flexion angle will be recorded in degrees.
|
Preoperatively and at 12 and 24 hours after surgery
|
|
Quality of Recovery at 24 Hours Assessed Using QoR-15
Időkeret: 24 hours after surgery
|
Recovery quality will be evaluated using the Quality of Recovery-15 (QoR-15) questionnaire.
Total scores range from 0 to 150, with higher scores indicating better postoperative recovery.
|
24 hours after surgery
|
|
Postoperative Nausea and Vomiting
Időkeret: Incidence of postopereative nausea and/ or vomiting within 48 hours
|
The severity of postoperative nausea and vomiting will be assessed using a 4-point ordinal scale (0-3), where 0 = none, 1 = mild, 2 = moderate, and 3 = severe.
Lower scores indicate fewer postoperative symptoms.
|
Incidence of postopereative nausea and/ or vomiting within 48 hours
|
|
Patient Satisfaction
Időkeret: 48 hours after surgery
|
Patient satisfaction with postoperative pain management will be assessed using a 5-point Likert scale, ranging from 1 (very dissatisfied) to 5 (very satisfied).
Higher scores indicate greater patient satisfaction.
|
48 hours after surgery
|
|
Surgeon Satisfaction
Időkeret: At completion of surgery
|
Surgeon satisfaction with perioperative conditions will be assessed using a 5-point Likert scale, ranging from 1 (very dissatisfied) to 5 (very satisfied).
Higher scores indicate greater surgeon satisfaction.
|
At completion of surgery
|
|
Length of Hospital Stay
Időkeret: From end of surgery to hospital discharge, assessed up to 10 days
|
Length of hospital stay will be defined as the time from completion of surgery until hospital discharge and will be recorded in hours.
Shorter hospital stay indicates earlier postoperative recovery.
|
From end of surgery to hospital discharge, assessed up to 10 days
|
|
Block-Related Adverse Events
Időkeret: From block placement to hospital discharge, assessed up to 10 days
|
The incidence of block-related adverse events, including neurological injury, foot drop, local anesthetic systemic toxicity, hematoma, infection, allergic reactions, and myotoxicity, will be recorded.
Outcomes will be reported as the number of participants experiencing each event.
|
From block placement to hospital discharge, assessed up to 10 days
|
Együttműködők és nyomozók
Nyomozók
- Kutatásvezető: Serhat Gulersen, MD,, University of Health Sciences Türkiye, Antalya Training and Research Hospital
Tanulmányi rekorddátumok
Tanulmány főbb dátumok
Tanulmány kezdete (Becsült)
Elsődleges befejezés (Becsült)
A tanulmány befejezése (Becsült)
Tanulmányi regisztráció dátumai
Először benyújtva
Először nyújtották be, amely megfelel a minőségbiztosítási kritériumoknak
Első közzététel (Tényleges)
Tanulmányi rekordok frissítései
Utolsó frissítés közzétéve (Tényleges)
Az utolsó frissítés elküldve, amely megfelel a minőségbiztosítási kritériumoknak
Utolsó ellenőrzés
Több információ
A tanulmányhoz kapcsolódó kifejezések
Kulcsszavak
További vonatkozó MeSH feltételek
Egyéb vizsgálati azonosító számok
- 10840098-202.3.02-446
Terv az egyéni résztvevői adatokhoz (IPD)
Tervezi megosztani az egyéni résztvevői adatokat (IPD)?
Gyógyszer- és eszközinformációk, tanulmányi dokumentumok
Egy amerikai FDA által szabályozott gyógyszerkészítményt tanulmányoz
Egy amerikai FDA által szabályozott eszközterméket tanulmányoz
Ezt az információt közvetlenül a clinicaltrials.gov webhelyről szereztük be, változtatás nélkül. Ha bármilyen kérése van vizsgálati adatainak módosítására, eltávolítására vagy frissítésére, kérjük, írjon a következő címre: register@clinicaltrials.gov. Amint a változás bevezetésre kerül a clinicaltrials.gov oldalon, ez a webhelyünkön is automatikusan frissül. .